Skip to main content

Table 1 Patient characteristics (at ICU admission and at the start of CytoSorb or CRRT)

From: Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study

CharacteristicsCytoSorb (N = 67)CRRT only (n = 48)Unadjusted p valuesIPTW-adjusted p value
Demography
 Age, years (Mean, SD)61.1 (14.7)68.7 (9.6)0.0010.126
 Male, n (%)37 (55%)30 (61%)0.5220.021
Comorbidity, n (%)
 Any comorbidity43 (64%)42 (88%)0.0020.601
 Diabetes mellitus type 214 (21%)20 (41%)0.0240.778
 Hypertension23 (34%)26 (53%)0.0460.409
 Coronary heart disease9 (13%)8 (16%)0.6670.064
 Heart failure (systolic/diastolic)4 (6%)10 (20%)0.0300.501
 Prior chronic kidney disease8 (12%)18 (37%)0.0030.002
 Peripheral artery disease10 (15%)8 (16%)0.8390.021
 Cerebrovascular accident6 (9%)3 (6%)0.5770.369
 COPD8 (12%)10 (20%)0.2330.002
Primary diagnosis, n (%)
 Abdominal sepsis31 (46%)12 (25%)0.0140.870
 Pneumosepsis14 (21%)21 (43%)0.0140.275
 Urosepsis2 (3%)6 (12%)0.0780.217
 Cutaneous/arthritis9 (13%)3 (6%)0.1820.064
 Vascular sepsis5 (8%)00.0240.026
 Cerebral sepsis01 (2%)0.3220.475
 Sepsis (unknown cause)6 (9%)6 (12%)0.5690.755
Admission
 Surgical (otherwise medical)27 (40%)6 (12%)< 0.0010.994
 Days on ICU9 (2–19)9 (3–13)0.7830.463
Hemodynamics (Mean, SD)
 Lactate at admission6.4 (5.1)4.4 (4.4)0.0270.421
 Lactate at the start of therapy6.9 (5.6)2.9 (3.1)< 0.0010.544
 Noradrenaline (μg/kg/min) adm.0.48 (0.55)0.29 (0.40)0.0520.073
 Noradrenaline (μg/kg/min) Rx0.96 (0.73)0.28 (0.36)< 0.0010.769
 Total duration noradrenaline (days)3 (1–5)3 (1–5)0.9790.222
 Duration noradrenaline from Rx (days)2 (1–3)1 (0–2)0.6940.989
 MAP at admission73 (19)74 (20)0.7480.418
 MAP at the start of therapy69 (15)77 (18)0.0070.019
Prognostic scores
 SOFA ICU admission11.7 (3.3)11.8 (3.5)0.9070.854
 SOFA at the start of treatment13.8 (2.8)12.8 (3.2)0.0670.239